Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis

Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis

Objective Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P1 receptor expression on cardiac cells is involved in cardiac conduction. We report cardiovascular treatment-emer...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiang Guo, Peter M Irving, Laurent Peyrin-Biroulet, Séverine Vermeire, Joseph Wu, Irene Modesto, David T Rubin, Marla C Dubinsky, Andres J Yarur, Miguel Regueiro, Martina Goetsch, Krisztina Lazin, Guibao Gu, Aoibhinn McDonnell, Jesse Green, Alexis B Dalam
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/12/1/e001516.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items